Assessing CL-Psychiatry Rates and Barriers to Recommending Naloxone and Opioid-Agonist Medications for Medically Hospitalized Patients with Opioid Use Disorder Robert Tessier, MD, MPH; Priya Gopalan, MD

UPMC Western Psychiatric Hospital

Introduction

- Hospitalizations of patients with opioid use disorder (OUD) represent opportunities for initiating evidence-based treatments to improve post-discharge outcomes.
- Medications for OUD (MOUD)
- Naloxone kits for overdose (OD prevention)
- Consultation-liaison (CL) psychiatrists evaluate patients w/OUD, creating critical opportunities to provide life-saving interventions at point of care.

Aims

- To determine if CL psychiatrists within our health system are recommending MOUD and naloxone to patients with active opioid use
- To identify **barriers and strategies to improve** these practices.




Chart Review Results

Demographics


Patients with active opioid use disorder (n)	129
Gender (n female (%))	65 (50.4%)
Age in years (average (range))	40.9 (21 – 73)
Marital Status (n married (%))	9 (7.0%)
Already prescribed MOUD (n (%))	29 (22.5%)

Patients with active opioid use (n (%))		
Patient not on MOUD – CL made MOUD recs	56 (56%)	
Recommended naloxone	11 (8.5%)	

Average time to consult order (mean days (95% CI))	
All	1.5 (.9 - 2.1)
Not currently on MOUD	1.4 (.8 - 2.0)
Received MOUD recs	2.1 (1.1 - 3.1)
Did NOT receive MOUD recs	0.4 (.36)

Average length of stay	
(mean days (95% CI))	

All	8.8 (6.6 - 10.9)
Not currently on MOUD	9.7 (7.1 - 12.4)
Received MOUD recs	11.6 (7.6 - 15.6)
Did NOT receive MOUD recs	7.3 (4.3 - 10.3)



Na

Discussion

month

week

1-2 times per

Most CL psychiatrists see patients with OUD frequently • Need to 个 recs for MOUD and OD prevention

• Consults prior to withdrawal symptoms emerging may confound recommendations

• CL psychiatrists believe in importance of MOUD and take-home naloxone Improvement needed in discussing/initiating MOUD, discussing OD prevention • Mismatch between comfort discussing OD prevention and recommending


naloxone • No interaction between attitudes, comfort, and time since completing residency/fellowship, MOUD training since residency, or clinical site

66.7%

Future Directions

 Mismatch between attitudes, comfort, and practice Semi-structured key-stakeholder interviews

• Possible interventions: training sessions, 1:1 coaching, pre-made order sets



Survey Scores

Attitudes and Comfort Likert score (1-5) (mean (95% CI)) Attitudes about MOUD 4.33 (4.10 - 4.57)

Attitudes about mood	4.55 (4.10 4.57)	
Attitudes about OD prevention	4.81 (4.37 - 5)	
Comfort discussing MOUD	3.86 (3.49 - 4.23)	
Comfort initiating MOUD	3.96 (3.76 - 4.16)	
Comfort discussing OD prevention	3.89 (3.53 - 4.25)	
Comfort recommending naloxone	4.63 (4.29 - 4.96)	
Comfort arranging follow-up	4.56 (4.33 - 4.79)	
erceived benefit from education topics Likert score (1-5) (mean (95% CI))		

Methadone	4.61 (4.23 - 4.99)
Buprenorphine	4.78 (4.53 - 5)
aloxone and OD prevention	4.33 (3.96 - 4.71)

Limitations

- Did not include follow-ups
- Does not account for primary teams ordering
- Attendings may not document verbal recs or orders placed
- Perceived knowledge may not equal actual knowledge

Citations

Herscher M, Fine M, Navalurkar R, Hirt L, Wang L. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients. Med Clin North Am. 2020 Jul;104(4):695-708.